Omega Therapeutics to Participate in Two Upcoming Investor Conferences
Omega Therapeutics (Nasdaq: OMGA) will participate in two investor conferences: the Jefferies Cell and Genetic Medicine Summit on September 30, 2022, and Chardan's 6th Annual Genetic Medicines Conference on October 4, 2022. The summit will feature a fireside chat at 9:00 a.m. ET, while the Chardan conference includes a gene regulation panel at 9:30 a.m. ET and another fireside chat at 11:00 a.m. ET. Webcasts will be available live on their website, and replays will be accessible for 90 days.
- None.
- None.
CAMBRIDGE, Mass., Sept. 26, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform, today announced that members of management will participate in two upcoming investor conferences.
Fireside Chat
Date: September 30, 2022
Time: 9:00 a.m. ET
Gene Regulation Panel
Date: October 4, 2022
Time: 9:30 a.m. ET
Fireside Chat
Date: October 4, 2022
Time: 11:00 a.m. ET
Live webcasts of the fireside chats and panel discussion will be available on the Investors & Media section of the Company's website at www.omegatherapeutics.com. An archived replay of the fireside chats will be available on the same website for approximately 90 days.
Omega Therapeutics, founded by Flagship Pioneering, is a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines. The company's OMEGA Epigenomic Programming™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth, and differentiation to cell death. Using a suite of technologies, paired with Omega's process of systematic, rational, and integrative drug design, the OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega's modular and programmable mRNA medicines, Omega Epigenomic Controllers™, are designed to target specific epigenomic loci within insulated genomic domains, EpiZips, from amongst thousands of unique, mapped, and validated genome-wide DNA-sequences, with high specificity to durably tune single or multiple genes to treat and cure diseases through Precision Genomic Control™. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases, including alopecia.
For more information, visit omegatherapeutics.com, or follow us on Twitter and LinkedIn.
Investor and Media Contact:
Eva Stroynowski
617-949-4370
estroynowski@omegatx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences-301631373.html
SOURCE Omega Therapeutics
FAQ
When is Omega Therapeutics participating in the Jefferies Cell and Genetic Medicine Summit?
What is the date and time of the Gene Regulation Panel at Chardan's conference?
Where can I watch the investor conference webcasts for Omega Therapeutics?
What is the focus of Omega Therapeutics' OMEGA Epigenomic Programming™ platform?
What type of company is Omega Therapeutics?
